Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure

Heart

Volumn 102, Issue 21, 2016, Pages 1742-1749

  Mealing, Stuart ^a   Woods, Beth ^b   Hawkins, Neil ^a   Cowie, Martin R ^c   Plummer, Christopher J ^d   Abraham, William T ^e   Beshai, John F ^f   Klein, Helmut ^g   Sculpher, Mark ^a,b  

^a ICON Clinical Research UK Ltd   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d FREEMAN HOSPITAL   (United Kingdom)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGED; ALL CAUSE MORTALITY; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DEVICE THERAPY; FEMALE; HEART EJECTION FRACTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART MUSCLE ISCHEMIA; HOSPITALIZATION COST; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MALE; MORTALITY; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; QRS INTERVAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC HEART FAILURE; UNITED KINGDOM; ADVERSE EFFECTS; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVERSION; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DEVICES; ECONOMIC MODEL; ECONOMICS; HEALTH CARE COST; HEALTH CARE QUALITY; HEART FAILURE, SYSTOLIC; HOSPITAL COST; HOSPITALIZATION; PATIENT SELECTION; TIME FACTOR; TREATMENT OUTCOME;

AGED; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; FEMALE; HEALTH CARE COSTS; HEART FAILURE, SYSTOLIC; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; MALE; MODELS, ECONOMIC; PATIENT SELECTION; PROCESS ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84978818133     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2015-308883     Document Type: Article

References (29)

1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235.
2. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
3. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-69.
4. Noyes K, Veazie P, Hall WJ, et al. Cost-effectiveness of cardiac resynchronization therapy in the MADIT-CRT trial. J Cardiovasc Electrophysiol 2013;24:66-74.
5. Linde C, Mealing S, Hawkins N, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction). Eur Heart J 2011;32:1631-9.
6. Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2006;114:135-42.
7. Al-Khatib SM, Anstrom KJ, Eisenstein EL, et al. Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med 2005;142:593-600.
8. Calvert MJ, Freemantle N, Yao G, et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J 2005;26:2681-8.
9. Feldman AM, de Lissovoy G, Bristow MR, et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005;46:2311-21.
10. Fox M, Mealing S, Anderson R, et al. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. Health Technol Assess 2007;11:iii-iv, ix-248.
11. Medical Services Advisory Committee Australian Government Department of Health and Aging. Cardiac resynchronisation therapy for severe heart failure. 2006. http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1FBFC70B8B62BA64 CA2575AD0082FDA4/File/1042-One-page-summary.pdf (accessed 9 Jun 2016).
12. Buxton M, Caine N, Chase D, et al. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and the modelling of cost-effectiveness and cost-utility for these groups in a UK context. Health Technol Assess 2006;10:iii-iv, ix-xi, 1-164.
13. National Institute for Health and Clinical Excellence. Implantable Cardioverter Defibrillators for Arrhythmias: Final Appraisal Determination. http://www.nice.org.uk/nicemedia/pdf/Arrhythmias-FAD.pdf
14. National Institute for Health and Clinical Excellence. Cardiac resynchronisation therapy for the treatment of heart failure: Final Appraisal Determination. http://www.nice.org.uk/nicemedia/pdf/Heartfailure-FAD.pdf
15. Woods B, Hawkins N, Mealing S, et al. Individual patient data network metaanalysis of mortality effects of implantable cardiac devices. Heart 2015;101:1800-6.
16. Association of British Healthcare Industries. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review of TA95 and TA120): Submission to The National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ta314/documents
17. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. https://www.nice.org.uk/article/pmg9/chapter/foreword
18. Briggs ACK, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford University Press; 2006.
19. Cleland JG, Freemantle N, Erdmann E, et al. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial. Eur J Heart Fail 2012;14:628-34.
20. Kind PHG, Macran S. UK Population Norms for EQ-5D. https://www.york.ac.uk/media/che/documents/papers/discussionpapers/CHE%20Discussion%20Paper% 20172.pdf
21. Cowie MR, Fox KF, Wood DA, et al. Hospitalization of patients with heart failure: a population-based study. Eur Heart J 2002;23:877-85.
22. Department of Health. NHS Reference costs 2012. https://www.gov.uk/government/collections/nhs-reference-costs
23. Curtis L. Unit costs of health and social care 2012 http://www.pssru.ac.uk/
24. British National Formulary. http://www.bnf.org/
25. National Institute for Health and Care Excellence. Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (review of TA95 and TA120): http://www.nice.org.uk/guidance/ta314/documents/arrythmias-icds-heart-failure-cardiac-resynchronisation-fad-document2
26. Goldenberg I, Gillespie J, Moss AJ, et al. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 2010;122:1265-71.
27. Brignole M, Auricchio A, Baron-Esquivias G, et al., The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Rev Esp Cardiol (Engl Ed) 2014;67:58.
28. Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008;52:1834-43.
29. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-38.